Main Article Content

Kanwal Arif Malik
Fahad Asim
Faiza Mohsin
Kanwal Mazhar
Rimsha Shahid
Sadia Zafar
Noor e Sehar Butt
Uneeb Asif
Malik Junaid Arif
Naba Shabbir
Mazhar Javed


Allergic Rhinitis (AR), Pharmacist, Intranasal Therapy (INT), Nasal Corticosteroids (NCS), McNamar


Background: Allergic rhinitis (AR) is a common disorder that is strongly linked to asthma and conjunctivitis. Intranasal therapy (INT) remains the backbone of allergic rhinitis management.

Aims: The present study aimed to assess the impact of pharmacist-led educational intervention on the management of AR.

Methodology: This prospective interventional study includes rhinitis patients from Quaid-i- Azam International Hospital and community pharmacists from pharmacy setups in Islamabad, Pakistan. Pre- and post-intervention competency was assessed and evaluated statistically. AR management of patients was evaluated through skin prick test and AR Control Questionnaire (ARC) scores.

Results: Registered pharmacists from 100 pharmacies were included in this study including 71% male and 29% female pharmacists (p value < 0.0001). All pharmacists were interviewed to assess their knowledge about AR, patients’ symptoms, and the management of Nasal Corticosteroid (NCS) usage in patients (7 days, 14 days or 1 month). Pharmacists were also categorized as competent and non-competent in NCS demonstration based upon the ability of pharmacists to demonstrate all the essential steps correctly with a total score of ≥ 5.

Conclusion: The data showed that before intervention only 24 pharmacists scored seven, demonstrating all the essential steps and were considered and classified as non-competent (p- value 0.05). McNamar tests analysis showed that pharmacists’ competence level was significantly improved from 29% before educational intervention to 48% after intervention (p- value 0.0057).

Abstract 196 | pdf Downloads 57


1. Bourdin A, Gras D, Vachier I and Chanez P (2009). Upper airway 1: Allergic rhinitis and asthma: united disease through epithelial cells. Thorax, 64(11): 925- 935.
2. Bousquet J, Van Cauwenberge P, Ait Khaled N, Bachert C, Baena‐ Cagnani C.E, Bouchard J, Bunnag C, Canonica GW, Carlsen KH, Chen YZ and Cruz AA (2006). Pharmacologic and anti‐ IgE treatment of allergic rhinitis ARIA update(in collaboration with GA2LEN). Allergy, 61(9): 1086-1096.
3. Bridgeman MB (2017). Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis. Integr Pharm Res Pract, 4(6): 109-119.
4. Di Lorenzo G, Pacor M, Pellitteri M., Morici G, Di Gregoli A, Lo Bianco C, Ditta V, Martinelli N, Candore G, Mansueto P and Rini GB (2004). Randomized placebo‐ controlled trial comparing fluticasone aqueous nasal spray in mono‐ therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plusmontelukast for seasonal allergic rhinitis. Clin Exp Allergy, 34(2): 259-267.
5. Dykewicz MS and Hamilos DL (2010). Rhinitis and sinusitis. J Allergy Clin Immunol, 125(2): 103-115.
6. Hoang MP, Chitsuthipakorn W, Seresirikachorn K and Snidvongs K improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared withmontelukast. Ann Allergy Asthma Immunol, 90(5): 536-542.
7. Kaszuba SM., Baroody FM, deTineo M, Haney L, Blair C and Naclerio RM (2001).
8. Superiority of an intranasal corticosteroid compared with an oral antihistamine inthe as- needed treatment of seasonal allergic rhinitis. Arch Int med, 161(21): 2581-2587
9. Laforce CF, Dockhorn RJ, Findlay SR, Meltzer EO, Nathan RA, Stricker W, Weakley S,Field EA and Rogenes PR(1994). Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract, 38(2): 145- 152.
10. Lohia S, Schlosser RJ and Soler ZM. (2013). Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta‐ analysis. Allergy, 68(5): 569-579.
11. Meltzer EO (2001). Quality of life in adults and children with allergic Rhinitis. JAllergy Clin Immunol, 108(1): 45-53.
12. Pullerits T, Praks L, Skoogh, BE, Ani R and Lotvall J (1999). Randomized placebo- controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergicrhinitis. Am J Respir Crit Care Med, 159(6):1814-1822
13. Ratner PH, Howland III WC, Arastu R, Philpot EE, Klein KC, Baidoo CA, Faris MA. and Rickard KA (2003). Fluticasone propionate aqueous nasal spray provided significantly greater Rhinitis. J Allergy Clin Immunol, 108(1): 45-53.
14. Siddiqui MI, Dhanani R and Moiz H (2020). Prevalence of allergic rhinitis among healthcare workers and its impact on their work: A cross-sectional survey at atertiary healthcare centre in Pakistan. J Pak Med Assoc, 70(8): 1432.
15. Siddiqui ZA, Walker A, Pirwani MM, Tahiri M and Syed I (2022). Allergic rhinitis: Diagnosis and management. Br J Hosp Med (Lond), 83(2): 1-9.
16. Small EO (2022). As- needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis. Rhinology, 60(4): 242-251.
17. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J and Georges G (2004). Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg, 131(3): 225-231.

Most read articles by the same author(s)